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Abstract
Background: Bi-allelic mutations in the genes Parkin (PARK2), PINK1 (PARK6) and DJ-1 (PARK7) are established causes
of autosomal recessive early-onset Parkinson’s Disease (EOPD). PINK1 mutations are the second commonest cause of
EOPD. Specific mutations may be relatively common in certain populations because of a founder effect. Homozygous
p.A217D PINK1 mutations were previously shown to cause EOPD in a large Sudanese kindred.
Case presentation: Here we report the segregation of homozygous PINK1 p.A217D mutations in a family originating
in Morocco with a history of parental consanguinity. From the clinical information available for the index case, the
phenotype of mild, slowly-progressive Parkinsonism is consistent with previous reports of p.A217D disease and of
PINK1 disease phenotype more generally. The reported features of early prominent lower-limb symptoms and gait
disturbance with asymmetrical onset are more frequent among PINK1 disease cases.
Conclusions: Together, reports of p.A217D in families of Moroccan and Sudanese origin suggest that p.A217D is a
North African mutation due to a founder effect. Wider genetic analyses of EOPD in North Africa would be useful to
estimate the prevalence of Parkinsonism caused by PINK1 p.A217D. In the absence of bi-allelic Parkin mutations,
PINK1 mutations should be considered in cases with evidence of autosomal recessive inheritance of EOPD and
presentation of atypical features such as early lower-limb symptoms and gait disturbance with asymmetrical
onset, which appear to be common in Mendelian EOPD.
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Background
Parkinson’s Disease (PD) is the second commonest neu-
rodegenerative disease, affecting approximately 1% of
people over 50 years of age [1]. PD is caused by progressive
selective death of dopaminergic neurons of the substantia
nigra pars compacta [2].
Although most PD is sporadic, the discovery of genetic
variants linked with PD in rare families with multiple
affected members has elucidated some of the pathogenic
mechanisms underlying neurodegeneration. In early-onset
Parkinson’s Disease (EOPD), genetic factors are probably
more prominent, as there is a consistently stronger effect
of familial aggregation compared to typical late onset PD
[3]. Increased disease risk for siblings of people affected by
EOPD as compared to parents is consistent with auto-
somal recessive disease.
Mutations in PARK2 (Parkin), PARK6 (PINK1) and
PARK7 (DJ-1) cause autosomal recessive EOPD. Parkin
point mutations and deletions are the commonest genetic
cause of EOPD, with worldwide prevalence of 8.6% in
EOPD. PINK1 mutations have intermediate prevalence of
3.7%, while DJ-1 mutations are rarer, accounting for 0.4%
of EOPD [4]. Causal mutations in Parkin, PINK1 and DJ-1
implicate disrupted mitochondrial homeostasis as a key
pathophysiologic event in EOPD. Amongst other diverse
functions, Parkin and PINK1 have a well-established
interactive role in mitochondrial quality control [5–7].
Over 40 point mutations and rarer large deletions in
PINK1 are reported to be pathogenic when inherited as
bi-allelic mutations in EOPD cases [8]. PINK1 mutation
prevalence varies with ethnicity, with greater prevalence
in Asian cases (13.5% among EOPD cases) compared to
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white or Latin American cases (<1% among EOPD cases)
[4]. Despite the large number of different PINK1 mutations
reported, individually each is rare [9]. The pathogenicity of
rare mutations shown to segregate with EOPD in just one
family is less certain. Identification of families showing
segregation of the same bi-allelic variant increases con-
fidence in its pathogenicity. Here we report a new fam-
ily with PINK1 disease.
Case presentation
Patients
The patients were of French North African descent, origin-
ating in Morocco. The siblings were born in France. The
kindred comprises two generations, of which two second-
generation family members had a Parkinsonian disorder
(Fig. 1a). One second-generation family member died
in 2006 in a road traffic accident. The parents were first
cousins.
DNA was available for four family members: two affected
(MF_1 [index] and MF_3) and one unaffected (MF_2).
Clinical history
Clinical information was only available for the index case
(MF_1), who developed symptoms in 2003, age 29 years
with tremor of the left hand, micrographia, slowness in
walking and a sensation of heavy legs. In 2005, symptoms
progressed, with a tendency to drag the right leg. MF_1
was first examined in 2009, age 34 and had bilateral
bradykinesia, rigidity, postural and rest tremor. Tremor
and rigidity were noticeably worse on the left. Additional
features included mild facial hypomimia, lower-limb hyper-
reflexia and eye movement ‘catch-up’ saccades without no-
ticeable slowness of eye movements in the vertical plane. A
DaTscan showed reduced dopamine receptor binding in
the putamen bilaterally consistent with nigrostriatal cell
loss. There were no signs of cognitive nor neuropsychiatric
disturbance, and tests for copper abnormalities, neuroferri-
tinopathy and adjusted calcium, liver and thyroid function
were normal. An MRI brain scan revealed no significant ab-
normality. MF_1 reported three falls within a twelve month
period but was independent in activities of daily living.
Symptoms were mild in the morning with deterioration as
the day progressed. MF_1 was prescribed rasagiline, with
some improvement in gait.
Six years after symptom onset a formal detailed assess-
ment was carried out. Motor assessment: MF_1 completed
parts II (‘motor aspects of experiences of daily living’) and
III (‘motor examination’) of the Movement Disorder
Society revised Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS; [10]) and recorded total scores of 7/52
and 38/429 respectively. Notable findings from the part
III motor examination were increased bradykinesia and
rigidity for the lower body compared with upper body,
with greater impairment on the left side. Hoehn and
Yahr stage was 2; classified as ‘bilateral impairment
without impairment of balance’ [11].
Neuropsychological assessment: MF_1’s scores were
both within the defined ‘normal’ range for both the Mon-
treal Cognitive Assessment (MoCA; [12]), Mini-Mental
State Examination (MMSE; [13]) and Geriatric Depression
Scale-15 [14].
Fig. 1 a Genetic pedigree of the family, with EOPD status indicated
by shaded diamonds. Arrow indicates index case. b Chromatographs
from sequencing with the c.650 position of PINK1 exon 2 highlighted.
Traces for affected family members MF_1 (index case) and MF_3 show
homozygous C > A transversions, while that of the ‘carrier’ MF_2 shows
a heterozygous transversion. c Multiple alignments of the PINK1 protein
in clustal format. Box indicates highly conserved ATPase orientation site.
Shading indicates the position of the p.A217D mutation
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Non-Motor Assessment: Scores for the Epworth Sleepi-
ness Scale [15] and overall sleep quality (Pittsburgh Sleep
Quality Index [16]) were normal. Responses to the Non-
Motor Symptoms Questionnaire (NMS-Quest; [17]) did
not indicate any significant abnormality of sleep, sphincter
or other autonomic function and there was no significant
postural drop in blood pressure.
In 2011 MF_1 reported making some typing mistakes
at work due to bradykinesia and reported some back and
shoulder pain. In 2012, symptoms had progressed, with
a gradual increase in slowness of movement and rigidity.
Tremor was mild, but speech had deteriorated, with more
noticeable dysarthrophonia. Symptoms responded well to
ropinirole, which MF_1 had been taking for around six
months at the time of examination. In 2012, MF_1 was
continuing to work full-time and walk to work every
morning. MF_1 was not taking L-DOPA.
Genetic analysis
Genetic analysis of the family was approved under the
Research Ethics Committee for Wales (Wales REC; 14/
WA/1179; Clinical Neurological Disease Bio-bank and
Neurogenetics Research Study 2 (CANDAS2)). Diagnos-
tic testing was performed for Parkin and LRRK2 only.
Whole exome sequencing was sought on the index case
to eliminate other established recessive mutations. Briefly,
sample libraries were prepared using Illumina capture kits
with paired-end sequencing performed on the Illumina
HiSeq2000. All reads were aligned using BWA against
the UCSC hg19 reference genome [18]. Variant calling
and quality-based filtering were done using GATK [19].
ANNOVAR [20] was used to annotate variants. Sanger
sequencing was performed to validate any identified
variants.
Initial genetic tests of the index case did not find a
Parkin or LRRK2 mutation. Subsequent whole exome se-
quencing confirmed absence of Parkin and LRRK2 mu-
tations, but revealed a homozygous p.A217D mutation
in PINK1 (rs74315360).
Sanger sequencing confirmed the p.A217D mutation
(Fig. 1b). Cases show homozygous C > A transversions
at c.650 (NM_032409.2:c.650C > A), resulting in an ala-
nine to aspartic acid substitution at position 217 of
PINK1. The unaffected family member analysed shows a
heterozygous transversion, identifying them as a carrier
of the p.A217D mutation. We have therefore identified
the genetic cause of this family’s EOPD.
Discussion and conclusions
Although PINK1 mutations are an established cause of
EOPD, to our knowledge this is the second report of the
PINK1 p.A217D mutation. p.A217D is a missense muta-
tion altering a highly-conserved amino acid of the kinase
domain in the ATPase orientation site of PINK1 (Fig. 1c).
p.A217D was predicted to be damaging by all six in silico
prediction tools from the genetic analysis [21–26]. Homo-
zygous PINK1 p.A217D mutations were previously found
to segregate with EOPD in a large Sudanese kindred, in
addition to its absence from 394 sequenced control chro-
mosomes [27]. The rarity of this mutation is confirmed by
its absence from the ExAC database (http://exac.broa-
dinstitute.org), comprising approximately 60,000 indi-
viduals, of which about 5000 are African or African-
American, likely to be of largely sub-Saharan origin
[28]. The finding that the homozygous p.A217D muta-
tion segregates with PD in this family of Moroccan ori-
gin adds weight to its pathogenic status.
Similarities between the clinical phenotype of the index
case here and that previously reported for homozygous
p.A217D PD cases are classical Parkinsonism and a
relatively benign disease course. The most prominent
difference is the later age at onset (AAO) of the cases
here (27–29 years) compared to the previous p.A217D
cases’ mean AAO of 12.6 years (range: 9–14 years).
The clinical phenotype reported here is consistent with
the documented PINK1 EOPD phenotype of relatively
mild, slowly progressive classical Parkinsonism [29–32].
An interesting feature of the index case’s disease here is
early, asymmetric gait disturbance. Lower limb symptoms
and particularly gait disturbance are typically late features
of idiopathic PD and usually accompanied by motor and
cognitive decline [33] but they appear to be prominent
early features of PINK1 disease [27, 34–36]. The index
case showed prominent lower limb hyper-reflexia upon
examination; hyper-reflexia has been reported to be more
frequent in PINK1 cases than cases without PINK1 muta-
tions or cases with Parkin mutations [32].
The literature on PINK1 EOPD suggests increased
prevalence of some non-motor PD symptoms compared
with idiopathic PD. These include mild cognitive impair-
ment [37–41] and psychiatric abnormalities such as
affective and behavioural disorders [34–36, 42, 43]. How-
ever prominent autonomic features, common in Lewy body
PD such as REM sleep behaviour disorder, constipation and
urinary symptoms are usually absent in Parkin and PINK1
disease. The index case in this study did not have significant
cognitive, neuro-psychiatric or autonomic clinical features.
In summary, EOPD cases with homozygous PINK1
p.A217D mutations reported here a) share most clinical
features with previously reported p.A217D cases except
with older AAO, b) are consistent with the previously
reported PINK1 EOPD phenotype more generally but
with earlier AAO and without cognitive or neuropsychi-
atric disturbance, and together with other reports support
the presence of features that add to a unique clinical
Parkinsonian phenotype associated with PINK1 mutations.
As the second report of p.A217D in cases originating
in North Africa, p.A217D is probably a North African
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PINK1 mutation. Specific PINK1 mutations have rela-
tively high frequency in some populations. For example
the p.L347P mutation has a carrier frequency of 8% in
the Philippines, indicating a founder effect [44]. Genetic
analysis is not widely performed in North Africa, so fur-
ther patients and kindreds may be found with PINK1
p.A217D disease.
In conclusion, we report the second occurrence of the
PINK1 p.A217D mutation in a family affected by EOPD.
Our result adds weight to the pathogenic status of this
mutation and expands knowledge of the geographic diver-
sity of p.A217D mutations to the Moroccan sub-region of
North Africa.
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